Avecho Biotechnology Limited

Equities

AVE

AU0000047441

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 02:10:45 2024-04-19 am EDT			5-day change	1st Jan Change
0.004 ^AUD	-20.00%		-20.00%	+14.29%

Mar. 25	Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial	MT
Mar. 14	Avecho to Push Forward with Phase III Trial of Anti-Insomnia Drug	MT

Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2021

August 23, 2021 at 06:41 pm EDT

Avecho Biotechnology Limited announced earnings results for the half year ended June 30, 2021. For the half year, the company announced sales was AUD 265,898 compared to AUD 196,989 a year ago. Net loss was AUD 1.737 million compared to AUD 872,487 a year ago. Basic loss per share from continuing operations was AUD 0.001 compared to AUD 0.0006 a year ago.

Latest news about Avecho Biotechnology Limited

Avecho Biotechnology Begins Patient Recruitment for Phase Three Anti-Insomnia Drug Trial	Mar. 25	MT
Avecho to Push Forward with Phase III Trial of Anti-Insomnia Drug	Mar. 14	MT
Avecho Biotechnology Secures Ethics Clearance for Phase Three Insomnia Trial	Mar. 07	MT
Avecho Biotechnology Limited Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-31	CI
Avecho Biotechnology Achieves Two-Year Stability Milestone for CBD Capsule	23-06-21	MT
US Patent Office Allows Avecho Biotechnology's Patent on 'Optimized' Manufacturing Method for Tocopheryl Phosphate Mixture	23-05-28	MT
Avecho Biotechnology Signs Licensing Deal with Arthur Group for Development of Cancer Drugs	23-05-22	MT
Avecho Biotechnology Begins Manufacturing for Oral Cannabidiol Capsules	23-05-17	MT
Avecho Biotechnology Raises AU$2 Million Via Entitlement Offer; Shares Slip 20%	23-05-08	MT
Avecho Biotechnology Conducts Entitlement Offer to Raise $11 Million to Fund Pivotal Phase Iii Clinical Trial	23-04-02	CI
Avecho Biotechnology Limited Auditor Raises 'Going Concern' Doubt	23-03-14	CI
Avecho Biotechnology Limited Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-27	CI
Avecho Biotechnology Expands Research Partnership for Cannabidiol Medication	23-02-22	MT
Avecho Biotechnology Limited Announces Ongoing Collaboration with Lambert Initiative	23-02-21	CI
Athenex Pharmaceutical Division Submits Avecho's Vitamin K Injection to US FDA	23-01-12	MT
Athenex Submits Avecho's Phytonadione to FDA Pre-IND	23-01-11	CI
Avecho Biotechnology Secures Ethics Approval for Phase 3 Insomnia Trial	22-12-22	MT
Avecho Biotechnology Limited Receives Ethics Approval for its Pivotal Phase III Clinical Trial Testing its Oral CBD Softgel Capsule for Insomnia	22-12-21	CI
Avecho Biotechnology Signs Development Deal for TPM-enhanced Ibuprofen Gel for US market; Shares Up 10%	22-12-20	MT
Avecho Biotechnology Limited Signs Development Agreement with Perrigo Company plc	22-12-19	CI
Avecho Biotechnology Validates Bioavailability of Cannabinoid Product in Canine Study	22-09-19	MT
Avecho Biotechnology Limited Announces Interim Results from Comparative Pharmacokinetic Studies Conducted in the Uk	22-09-18	CI
Avecho Biotechnology Limited Reports Earnings Results for the Half Year Ended June 30, 2022	22-08-28	CI
Avecho Biotechnology Validates Efficacy of CBD Topical Gel Product in Hand Osteoarthritis Study; Shares Jump 8%	22-03-28	MT

Chart Avecho Biotechnology Limited

Duration

Period

More charts

Company Profile

Avecho Biotechnology Limited is an Australia-based biopharmaceutical company. The Company develops and commercializes human and animal health products using its drug delivery system called Tocopheryl Phosphate Mixture (TPM). TPM is derived from vitamin E using patented processes. The Company's segments include Production and Human Health. The Production segment manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health portfolio covers delivery of pharmaceutical products through gels, injectables and patches, including conduct of research and development activities. The Company's products pipeline includes Weaner Pig Starter TPM Premix, Poultry TPM Premix, Dairy TPM Premix, Daptomycin, Propofol and Veterinary Applications. The Company is also developing TPM to enhance feed efficiency and the health of livestock. Its TPM products are commercialized under license: Voveran TPM Gel, Instanac TPM Gel, Vital ET, and Ashland TPM.

Sector

Biotechnology & Medical Research

Calendar

2024-05-29 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
AVECHO BIOTECHNOLOGY LIMITED	+14.29%	10.2M
IQVIA HOLDINGS INC.	-1.82%	41.35B
LONZA GROUP AG	+41.98%	40.38B
MODERNA, INC.	+2.56%	39.05B
CELLTRION, INC.	-12.11%	26.67B
ICON PUBLIC LIMITED COMPANY	+3.09%	24.07B
ALNYLAM PHARMACEUTICALS, INC.	-24.16%	18.36B
MEDPACE HOLDINGS, INC.	+22.12%	11.6B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.74%	11.68B
UNITED THERAPEUTICS CORPORATION	+7.75%	11.15B

Other Biotechnology & Medical Research